



**Amrita**  
THERAPEUTICS

# **2nd Annual Global Forum on Innovation, Creativity, and Intellectual Property**

**“Promiscuous Drugs of the  
Future”**

**Ananda M. Chakrabarty, PhD**  
Distinguished University Professor  
University of Illinois at Chicago

**Hyatt Regency Mumbai**  
February 26, 2008



**Amrita**  
THERAPEUTICS


# Amrita Therapeutics Pvt., Ltd

- Current Industry Trend: Targeted Drugs
- Drugs of the Future: Promiscuous Drugs
- Pathogen – Pathogen Interaction
- Direct Hit on the Disease Agent
- Preventing the Reappearance of the Disease Agent
- Bolstering the Immune System



Amrita  
THERAPEUTICS

# A Direct Hit!



# Bolstering Immunity: (Toll – like Receptors)




Fig. 6




**Amrita**  
THERAPEUTICS

# Preventing Recurrence:


- Oncogenic Transformation:

Figure 1A

Comparison of glands with or without lesions in an enlarged picture



Lesions




No Lesions

Figure 2

EFFECT OF CDG-P28 ON DMBA-INDUCED MAMMARY ALVEOLAR LESIONS IN ORGAN CULTURE

Group No.	Treatment	No. Glands per group	Glands with lesions	Percent Incidence	Percent Inhibition
1	DMBA	15	12	80.0	
2	DMBA + 12.5ug/ml	15	6	40.0	50%
3	DMBA + 25ug/ml	15	4	26.7	67%
4	DMBA + 50ug/ml	15	4	26.7	67%
5	DMBA + 100ug/ml	15	3	20.0	75%
6	DMBA + Azurin 50ug/ml	15	4	26.7	67%

Comments: Effective  
Non-Toxic  
IC50=12.5ug/ml




# Preventing Recurrence:


- Oncogenic Transformation (2)

**Figure 3**

Examples of DMBA-induced mammary ductal lesions



Control DMBA alone



DMBA + Azurin (50ug/ml)


DMBA + P28 (50ug/ml)

**Figure 4**

**EFFECT OF CDG-P28 ON DMBA-INDUCED MAMMARY DUCTAL LESIONS IN ORGAN CULTURE**

Chemopreventive agent:		P28			
Experiment No.:		CDG-2			
Group No.	Treatment	No. of fields examined	Fields with ductal lesions	Multiplicity %	Percent Inhibition
1	DMBA	90	57	63.3	
2	DMBA+ 12.5ug/ml	67	36	53.7	15%
3	DMBA + 25ug/ml	75	14	18.7	71%
4	DMBA + 50ug/ml	86	16	18.6	71%
5	DMBA + 100ug/ml	96	12	12.5	80%
6	DMBA + Azurin 50ug/ml	61	8	13.1	79%

Comments: Effective  
Non-Toxic  
IC50=<25µg/ml



# Laboratory members

